Xenon Pharmaceuticals (NASDAQ:XENE) Insider Christopher John Kenney Sells 2,771 Shares of Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Christopher John Kenney sold 2,771 shares of Xenon Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $166,564.81. Following the sale, the insider owned 4,729 shares of the company’s stock, valued at approximately $284,260.19. This trade represents a 36.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Xenon Pharmaceuticals Stock Down 1.2%

Shares of XENE traded down $0.72 on Thursday, hitting $58.33. 295,435 shares of the stock traded hands, compared to its average volume of 1,320,158. Xenon Pharmaceuticals Inc. has a 1 year low of $26.74 and a 1 year high of $63.95. The stock’s 50 day moving average is $43.23 and its two-hundred day moving average is $41.69. The firm has a market capitalization of $4.85 billion, a P/E ratio of -13.30 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the previous year, the firm earned ($0.84) EPS. Research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Neo Ivy Capital Management acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter valued at about $2,001,000. JPMorgan Chase & Co. increased its holdings in shares of Xenon Pharmaceuticals by 11.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after acquiring an additional 142,452 shares during the last quarter. Marshall Wace LLP increased its stake in Xenon Pharmaceuticals by 34.6% during the second quarter. Marshall Wace LLP now owns 1,020,254 shares of the biopharmaceutical company’s stock valued at $31,934,000 after purchasing an additional 262,109 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter valued at about $21,280,000. Finally, Westfield Capital Management Co. LP raised its position in shares of Xenon Pharmaceuticals by 4.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,206,066 shares of the biopharmaceutical company’s stock worth $48,424,000 after purchasing an additional 53,461 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

Key Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 efficacy readout — Xenon’s azetukalner met its goal in the focal-onset seizures study (X-TOLE2), and management plans an NDA filing in Q3 2026, materially derisking the lead program and supporting near-term commercial value. Zacks: Azetukalner Study
• Positive Sentiment: Major capital raise — Xenon priced an upsized offering to raise roughly $650M at $57.00/share (with an underwriter option to add shares), which substantially strengthens the balance sheet to fund Phase 3/commercial work and reduces near-term financing risk. GlobeNewswire: Offering
• Positive Sentiment: Analyst optimism and higher price targets — Several firms boosted targets and reiterated buys (Deutsche Bank to $90, HC Wainwright to $74, Wells Fargo to $68, Needham bullish), which can drive buying interest and momentum. Deutsche Bank PT HC Wainwright Note
• Neutral Sentiment: HC Wainwright updated multi-year EPS forecasts (improving FY2028–FY2030 but nudging FY2027 slightly worse); the revisions show evolving model assumptions tied to program timing and commercialization, but remain estimates that can change with trial/regulatory developments. HC Wainwright EPS Revision
• Negative Sentiment: Insider selling — CEO Ian Mortimer and other insiders disclosed large open-market sales (Mortimer sold ~270k shares and others sold several thousand), substantially reducing insider ownership and potentially signaling liquidity-taking or governance concerns for some investors. SEC Filing: Insider Sales
• Negative Sentiment: Dilution risk — while the $650M raise boosts runway, the sizable share issuance (and potential additional underwriter option) increases outstanding shares and may pressure near-term per-share metrics. GlobeNewswire: Offering

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Chardan Capital upgraded shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Wedbush upped their price objective on Xenon Pharmaceuticals from $47.00 to $64.00 and gave the stock an “outperform” rating in a report on Tuesday. JPMorgan Chase & Co. increased their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Jefferies Financial Group set a $100.00 target price on Xenon Pharmaceuticals in a report on Monday. Finally, Guggenheim reissued a “buy” rating and set a $90.00 price target on shares of Xenon Pharmaceuticals in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Xenon Pharmaceuticals has an average rating of “Buy” and an average price target of $71.94.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.